GlassScriptPhysician profile
Christopher W Marx
NPI 1811958929
$3,686.93
in general payments reported to CMS, 2019-2025
31 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $333 · 2021: $262 · 2022: $287 · 2023: $312 · 2024: $467 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.59 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $622.04 | 2019-2024 | Farxiga, Lokelma |
| Lilly USA, LLC | $604.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $258.45 | 2019-2024 | Freestyle Insulinx |
| Abbvie INC. | $245.40 | 2019-2025 | |
| Novo Nordisk INC | $243.83 | 2019-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $227.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.83 | 2019-2025 | Jardiance, Tradjenta |
| Dexcom, INC. | $180.90 | 2019-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $144.89 | 2019-2025 | Omnipod |
| Shire North American Group INC | $102.74 | 2019 | |
| Neurocrine Biosciences, INC. | $91.39 | 2024-2025 | |
| Amgen INC. | $88.71 | 2019-2025 | Tepezza, Evenity, Prolia |
| Tandem Diabetes Care, INC. | $77.33 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Becton, Dickinson and Company | $76.53 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $66.00 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $61.01 | 2019 | |
| Valeritas, INC. | $59.11 | 2019 | |
| Kyowa Kirin, INC. | $49.74 | 2025 | |
| Recordati_rare_diseases_inc. | $40.94 | 2025 | Isturisa |
| Aurinia Pharma U.S., INC. | $35.36 | 2024-2025 | Lupkynis |
| Beta Bionics, INC. | $33.09 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $27.01 | 2025 | Yorvipath |
| Medtronic, INC. | $24.78 | 2024 | Minimed 780g |
| Mannkind Corporation | $21.72 | 2023 | Afrezza |
| Mallinckrodt Hospital Products INC. | $21.35 | 2024 | Acthar |
| Zealand Pharma US, INC. | $19.62 | 2021 | |
| Antares Pharma, INC. | $17.49 | 2024 | Xyosted |
| Exact Sciences Corporation | $17.03 | 2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $15.54 | 2024 | Gvoke Hypopen |
| Amphastar Pharmaceuticals, INC. | $13.90 | 2024 | |
| Tolmar, INC. | $13.47 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Marx listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.